Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123069 | 0.79 | MAPKAPK2 (0.65) | EGFRMAPKAPK2 | |
| SCHEMBL16100702 | 0.69 | MAPKAPK2 (0.68) | MAPKAPK2 | |
| SCHEMBL16101729 | 0.69 | MAPKAPK2 (0.68) | MAPKAPK2 | |
| SCHEMBL16123244 | 0.69 | MAPKAPK2 (0.68) | MAPKAPK2 | |
| SCHEMBL16123306 | 0.68 | MAPKAPK2 (0.54) | EGFRMAPKAPK2 | |
| SCHEMBL17361151 | 0.68 | MAPKAPK2 (0.54) | EGFRMAPKAPK2 | |
| SCHEMBL16101785 | 0.67 | MAPKAPK2 (0.75) | MAPKAPK2 | |
| SCHEMBL16100274 | 0.66 | MAPKAPK2 (0.63) | MAPKAPK2 | |
| SCHEMBL16123216 | 0.65 | MAPKAPK2 (0.66) | MAPKAPK2BRD4CREBBP | |
| SCHEMBL16123119 | 0.64 | MAPKAPK2 (0.77) | EGFRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |